- 双特异性抗体的进步 -
The track on Advancing Bispecifics and Combination Therapy to the Clinic features case studies for haematological and solid tumours, bispecific-like products and biotherapeutics in combination. Presenters explain the rationale for the choice of combination, the background to the mode of action and how the products perform, as well as PK profile, PK/PD relationships, safety/toxicology studies, getting the right potency: side effect balance, translational studies, and risk assessment. Where appropriate, investigators present clinical trial design, demonstration of safety, issues that have arisen and have been resolved, proof of concept, dose escalation studies, and interaction with clinicians.


Preliminary Agenda


KEYNOTE: Development of Effective Combination Therapies for Immuno-Oncology
Rakesh Dixit, PhD, Global Head, Biologics Safety Assessment, Medimmune, Inc.

ENRICHMENT OF IMMUNE CELLS, ENGAGEMENT OF NK CELLS, AND BLOCKADE OF MACROPHAGES

Multispecific Antibody Technology Engaging NK Cells in Oncology
Laurent Gauthier, PhD, Senior Director, R&D, Innate Pharma SA

Application of Anti-Calin Technology for Enrichment of Immune Cells in the Tumour Microenvironment
Shane Olwill, PhD, Vice President and Head, Pieris Pharmaceuticals

T-CELL ENGAGEMENT: FOCUS ON OVERCOMING TOXICITY WHILE ENHANCING POTENCY IN SOLID AND LIQUID TUMOURS

Development of Novel Fully Human Bispecific Antibodies for Oncology
Eric Smith, PhD, Director, Bispecific Antibodies, Regeneron Pharmaceuticals

CD20 TCB (RG6026), A Novel “2:1” T Cell Bispecific Antibody for the Treatment of B Cell Malignancies
Marina Bacac, PhD, Head, Cancer Immunotherapy, Roche Innovation Center Zurich

Case Study on the CD3xCD20 Bispecific Antibody Program
Ida Hiemstra, PhD, Lead Scientist, Translational Research, Genmab

CHECKPOINT INHIBITORS: IN COMBINATION, AND TOGETHER WITH AGONISTS

Development of an Agonist Redirected Checkpoint, SIRPa-Fc-CD40L, for Cancer Immunotherapy
Taylor H. Schreiber, MD, PhD, CSO, Shattuck Labs, Inc.

ATOR-1015, A Next Generation, Bispecific CTLA-4 x OX40 Targeting Antibody for Tumor Directed Immunotherapy of Cancer
Christina Furebring, PhD, Senior Vice President, Research, Alligator Bioscience AB

CYTOKINE FUSION PROTEINS ENGINEERED FOR TUMOUR TARGETING AND CONTROL OF TOXICITY

Engineering Bispecific Cytokine-Fc Fusions to Create Safer and More Effective Immuno-Oncology Therapies
David Szymkowski, PhD, Vice President, Cell Biology, Xencor

Immunostimulatory Properties of a Novel IL-15-Based Tumor Targeted Immunocytokine
Anika Jäkel, PhD, Director, Preclinical Pharmacology & Cancer Immunology, Glycotope GmbH

 NEW PRODUCTS

Case Study on New Product: Biology and Proof of Concept
Mihriban Tuna, PhD, Vice President, Drug Discovery, F-star

Sponsored Presentation

Development and Application of MOA-Based Reporter Bioassays for Immunotherapy Drug Development
Mei Cong, Director, Custom Assay Services, Promega Corporation




* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English